Update on the emerging role of telavancin in hospital-acquired infections

Ther Clin Risk Manag. 2015 Apr 13;11:605-10. doi: 10.2147/TCRM.S57376. eCollection 2015.


Telavancin is a lipoglycopeptide that has activity against Gram-positive aerobic and anaerobic bacteria. It has activity against methicillin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus and non-Van-A strains of vancomycin-resistant enterococci. It has been approved by the US Food and Drug Administration (FDA) for complicated skin and skin structure infections and hospital-acquired pneumonia. There is a need for more clinical studies to determine the role of telavancin in treating bacteremia and prosthetic device infections. In this review, we discuss the published data on the use of telavancin in treating hospital-acquired infections and provide an update on new research.

Keywords: Staphylococcus aureus; linezolid; telavancin; vancomycin.

Publication types

  • Review